Amphenol Corporation (NYSE: APH) (the "Company" or "Amphenol"), as part of its completed acquisition (the "CCS Acquisition") ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

Detailed price information for Adc Therapeutics Sa (ADCT-N) from The Globe and Mail including charting and trades.

Agree Realty and Essential Properties Realty Trust are very popular net lease REITs. Read why ADC stock is better to own ...

Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line ...

Detailed price information for Agree Realty Corp (ADC-N) from The Globe and Mail including charting and trades.

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted ...

The Chinese biopharmaceutical company shared its recent innovations and strategic roadmap at the prestigious annual healthcare investment gathering, highlighting its development pipeline and growth ...

Tahoe Therapeutics and Alloy Therapeutics announced today that they are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard ...

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical ...